In Brief Yolanda Sanchez named director and CEO at UNM Comprehensive Cancer Center December 16, 2022Vol.48 No.45
In Brief The Max Foundation to make Novartis’s Scemblix available in low- & middle-income countries December 16, 2022Vol.48 No.45
Funding Opportunities FDA issues RFAs to study novel approaches to support therapeutic development in ultra-rare cancers December 16, 2022Vol.48 No.45
Funding Opportunities Fight Colorectal Cancer funds Tempus research fellowship to identify gaps in colorectal cancer research December 16, 2022Vol.48 No.45
Clinical Roundup Imbruvica + venetoclax demonstrates efficacy and sustained response in older patients with previously untreated CLL December 16, 2022Vol.48 No.45
Clinical Roundup Phase III study shows long-term results of Darzalex-based regimen in newly diagnosed, transplant-ineligible MM December 16, 2022Vol.48 No.45
Clinical Roundup Phase II data on Regeneron’s linvoseltamab show clinically meaningful responses in heavily pre-treated MM December 16, 2022Vol.48 No.45
Clinical Roundup Positive phase II data reported on Regeneron’s odronextamab in R/R DLBCL December 16, 2022Vol.48 No.45
Drugs & Targets FDA approves updated drug labeling for Xeloda tablets under Project Renewal December 16, 2022Vol.48 No.45
